



eFigure 1. Study design follow-up time points



eFigure 2. Kaplan Meier curve for time to normal mRS (mRS <2) and time to normal CASE (CASE <6)



eTable 1. Univariate linear regression models for baseline MOCA scores

	N Used	Parameter Estimate (SE)	p-value
Baseline mRS (1 unit increment)	17	-2.68 (0.85)	0.007
Baseline CASE (1 unit increment)	17	-1.45 (0.50)	0.011

SE: Standard Error

eTable 2. Bivariate mixed-effect models for moderate mRS

	OR (95% CI)	p-value
Female	6.49 (0.92, 45.79)	0.060
Hospital Admission	20.33 (0.92, 451.19)	0.057
Status Epilepticus	0.64 (0.06, 7.42)	0.72
FBDS	2.94 (0.42, 20.37)	0.27
Abnormal CSF	1.84 (0.18, 18.50)	0.60
Malignancy	1.54 (0.17, 13.91)	0.70
MRI: Abnormal Temporal Lobe	16.50 (2.29, 119.16)	0.006
Treatment Group 2	5.47 (0.13, 234.02)	0.37
Treatment Group3	6.39 (0.14, 295.85)	0.34
Treatment Group4	7.51 (0.07, 766.70)	0.39
Any long-term immunotherapy	5.69 (0.20, 163.10)	0.31
Number of Hospital Admission	1.71 (0.93, 3.15)	0.086
MOCA	0.68 (0.47, 0.98)	0.041

OR: odds ratio; CI: confidence interval; Each row represents a separate model adjusted for months since symptom onset

eTable 3. Bivariate mixed-effect models for CASE

	Parameter Estimate (SE)	p-value
Female	2.11 (0.97)	0.030
Hospital Admission	1.68 (1.23)	0.17
Status Epilepticus	2.02 (1.20)	0.092
FBDS	0.38 (1.02)	0.71
Abnormal CSF	0.69 (1.26)	0.58
Malignancy	1.73 (1.09)	0.11
MRI: Abnormal Temporal Lobe	2.00 (1.03)	0.053
Treatment Group 2	2.06 (1.64)	0.21
Treatment Group 3	1.18 (1.64)	0.47
Treatment Group 4	0.94 (2.15)	0.66
Any long-term immunotherapy	1.55 (1.47)	0.29
Number of Hospital Admission	0.37 (0.23)	0.11

MOCA	-0.22 (0.13)	0.095
------	--------------	-------

SE: Standard Error; Each row represents a separate model adjusted for months since symptom onset